The association between glucagon-like peptide-1 receptor agonists and reported musculoskeletal adverse events: a systematic review and meta-analysis of randomized controlled trials
Therapeutic Advances in Musculoskeletal Disease
Published online on February 28, 2026
Abstract
Therapeutic Advances in Musculoskeletal Disease, Volume 18, January-December 2026.
Background:Obesity is a major risk factor for musculoskeletal disorders. Glucagon-like peptide-1 receptor (GLP-1R)–based agonists facilitate weight loss and may influence musculoskeletal health. However, whether GLP-1R based agonists are associated with ...
Background:Obesity is a major risk factor for musculoskeletal disorders. Glucagon-like peptide-1 receptor (GLP-1R)–based agonists facilitate weight loss and may influence musculoskeletal health. However, whether GLP-1R based agonists are associated with ...